LXR

Liver X receptor

LXRs (Liver X Receptor α and β) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors.

LXRα is expressed predominately in some tissues, including the liver, kidney, macrophages, and adipose tissue. However, LXRβ is ubiquitously expressed. Activating LXRα (mainly expressed in liver) results in high triglyceride production, and growing evidence suggests that selective LXRβ agonists can reduce this side effect.

LXR Inhibitors, Agonists, Antagonists, Activators & Modulators

(20S)-Protopanaxatriol

(20(S)-APPT; g-PPT) Cat. No.: HY-N0835

(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the **glucocorticoid receptor (GR)** and **oestrogen receptor (ER)**, and is also a **LXRα** inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.



Purity: 98.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

24(S)-Hydroxycholesterol

(24S-OHC; 24S-HC; Cerebrosterol) Cat. No.: HY-16940

24(S)-Hydroxycholesterol (24S-OHC), the major brain cholesterol metabolite, plays an important role to maintain homeostasis of cholesterol in the brain.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg

24-Hydroxycholesterol

Cat. No.: HY-N2370

24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of **N-Methyl-d-Aspartate (NMDA) receptorsR**, and a potent activator of the transcription factors **LXR**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

27-Hydroxycholesterol

Cat. No.: HY-N2371

27-Hydroxycholesterol is a selective **estrogen receptor** modulator and an agonist of the **liver X receptor**.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetyl podocarpic acid anhydride

(Acetylpodocarpic dimer; APD) Cat. No.: HY-125772

Acetyl podocarpic acid anhydride is a potent, semisynthetic **liver X receptor(LXR)** agonist derived from extracts of the mayapple.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ876

Cat. No.: HY-18282

AZ876 is a potent and high-affinity **LXR** agonist. AZ876 displays 25-fold and 2.5-fold more potent than GW3965 (HY-10627) on human (h)LXRα and hLXRβ respectively.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-779788

(EXEL04286652; XL-652; BMS-788) Cat. No.: HY-19919

BMS-779788 is a **LXR** partial agonist with **IC_{50}** values of 68 nM for LXRα and 14 nM for LXRβ.



Purity: 98.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

DMHCA

Cat. No.: HY-129098

DMHCA, a potent and selective **LXR** agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

GSK2033

Cat. No.: HY-108688

GSK2033 is a **LXR** antagonist with **pIC_{50}**s of 7 and 7.4 for **LXRα** or **LXRβ**, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3987

Cat. No.: HY-123402

GSK3987 is a pan **LXRα/β** agonist with **EC_{50}**s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GW3965

Cat. No.: HY-10627

GW3965 is a potent, selective **liver X receptor (LXR)** agonist with EC_{50}s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GW3965 hydrochloride

Cat. No.: HY-10627A

GW3965 hydrochloride is a potent and selective **liver X receptor (LXR)** agonist with EC_{50}s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gymnestrogenin

Cat. No.: HY-N2273

Gymnestrogenin is a pentahydroxytriterpene from the leaves of Gymnema sylvestre R.Br. Gymnestrogenin is a **LXR** antagonist with IC_{50}s of 2.5 and 1.4 μM for LXRα and LXRβ transactivation, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Iristectorigenin B

(Iristectrigenin B)

Cat. No.: HY-N2509

Iristectorigenin B (Iristectrigenin B) is a liver X receptor (**LXR**) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LXR agonist 1

Cat. No.: HY-144549

LXR (Liver X receptor) agonist 1 is potent **LXR** agonist with AC_{50}s of 1.5 nM and 12 nM for **LXR-α** and **LXR-β**, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LXR-623

(WAY 252623)

Cat. No.: HY-10629

LXR-623 is a brain-penetrant partial **LXRα** and full **LXRβ** agonist, with IC_{50}s of 24 nM and 179 nM, respectively.



Purity: 99.48%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

LXRβ agonist-2

Cat. No.: HY-100469

LXRβ agonist-2 is a highly potent and β-selective liver X receptor **(LXRβ)** agonist with EC_{50} of 7 nM, displays 28.5-fold selectivity over LXRα (EC_{50}=200 nM) and used in the treatment of atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nagilactone B

Cat. No.: HY-N3216

Nagilactone B is a liver X receptor (**LXR**) agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

RGX-104

Cat. No.: HY-111498A

RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor **(LXR)** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RGX-104 hydrochloride

Cat. No.: HY-111498

RGX-104 hydrochloride is a small-molecule **LXR** agonist that modulates innate immunity via transcriptional activation of the ApoE gene.



Purity: 99.96%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rovazolac

Cat. No.: HY-109073

Rovazolac is a **liver x receptor (LXR)** modulator extracted from patent WO2013130892A1.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Saikosaponin A

Cat. No.: HY-N0246

Saikosaponin A is an active component of Bupleurum falcatum, up-regulates **LXRα** expression, with potent anti-inflammatory activity.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SR9238

Cat. No.: HY-101442

SR9238 is a synthetic **liver X receptor (LXR)** inverse agonist with **IC_{50}**s of 214 nM and 43 nM for **LXRα** and **LXRβ**, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

SR9243

Cat. No.: HY-16972

SR9243 is a **liver-X-receptor (LXR)** inverse agonist that induces LXR-corepressor interaction.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

T0901317

Cat. No.: HY-10626

T0901317 is an orally active and highly selective **LXR** agonist with an **EC_{50}** of 20 nM for LXRα. T0901317 activates **FXR** with an **EC_{50}** of 5 μM. T0901317 is **RORα** and **RORγ** dual inverse agonist with **K_i** values of 132 nM and 51 nM, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

XL041

(BMS-852927)

Cat. No.: HY-101973

XL041 (BMS-852927) is an **LXRβ**-selective agonist.



Purity: 99.44%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Yamogenin

(Neodiosgenin)

Cat. No.: HY-N2078

Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg